Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Open, Parallel, Phase 4 Study to Compare the Efficacy and Safety Between High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in High ASCVD Risk Patients With Type 2 diabEtes (CREATE Study)

NCT03403556 is registered in ClinicalTrials.gov with Yuhan Corporation as lead sponsor.

NCT NCT03403556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03403556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Open, Parallel, Phase 4 Study to Compare the Efficacy and Safety Between High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in High ASCVD Risk Patients With Type 2 diabEtes (CREATE Study)
Lead sponsor
Yuhan Corporation
Phase
Phase 4
Overall status
Unknown status
Start date
March 27, 2018
Completion date
December 31, 2021
Enrollment
140 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerotic cardiovascular disease, type 2 diabetes